March 31, 2008 - As part of the Philips cath lab showcase at ACC, the company presented Live 3D TEE technology for the cath lab, designed to give real-time volume rendered images using one-touch controls.

March 31, 2008 - The direct renin inhibitor aliskiren was found to be as effective as the angiotensin receptor blocker, losartan, currently considered the gold standard for regressing left ventricular hypertrophy (LVH), according to results from the ALLAY (The ALiskiren Left Ventricular Assessment of HypertrophY) presented today at the American College of Cardiology's 57th Annual Scientific Session (ACC.08).

Many patients with hypertension develop increased heart mass, known as LVH, which is a marker of cardiac end-organ damage and a powerful predictor of adverse outcomes.

March 31, 2008 – Philips brought to ACC its Xper Information Management, a personalized cardiovascular workflow solution that presents a variety of new features for reporting, image review, scheduling, inventory and intelligent data management.

Xper Information Management revolves around the clinician’s workflow. More than a cath lab solution, it also encompasses pre- and post-cath holding, physician review with reporting and administrative management. Our user-oriented, fully integrated technology offers a variety of advantages including:

April 1, 2008 - Philips at ACC 2008 displayed its cardiovascular IT, the enhanced Xcelera solution, an integrated multimodality that reportedly providing a single access point for all relevant cardiology information.

This single access point proves information for cardiovascular ultrasound, CT, MR, nuclear medicine, ECGs and electrophysiology recording signals, as well as long-term storage and enterprise distribution of multimedia studies. It gives one workspace for documenting, viewing, reporting and managing cardiovascular data, said Philips.

March 31, 2008 — When a clot develops inside a coronary stent, it can block blood flow to the heart, potentially causing a heart attack or even death. A single incident of stent thrombosis is bad enough, but a new study suggests that one in six patients can expect to experience at least one repeat episode. According to the Dutch Stent Thrombosis Study, among the strongest predictors of recurrent stent thrombosis is implantation of an additional stent during emergency treatment of the first episode.

March 31, 2008 - Percutaneous coronary intervention (PCI) can be performed safely and successfully in medical centers without on-site cardiac surgical back-up, provided programs are well-organized, highly skilled and committed to quality.

March 31, 2008 – Toshiba featured its AquilionONE at ACC 2008, an advanced diagnostic imaging system that can image an entire organ in a single rotation or over multiple rotations, showing real-time dynamic movement. With this system, it is possible to image an entire organ in a single rotation, for the first time, ensuring greater accuracy and diagnostic confidence and covering up to 16 centimeters of anatomy using 320 ultra high resolution 0.5-millimeter detector elements.

March 31, 2008 – Toshiba brought to ACC its Advanced Image Processing (AIP) technology for its Infinix X-ray product line, created to help users better visualize even the smallest interventional devices, featuring a programmable image display that reportedly gives clinicians the ability to optimize image viewing based on clinical preferences.

March 31, 2008 - Although drug-eluting stents have become widely used for the treatment of stable coronary artery disease, many cardiologists choose bare-metal stents for patients with heart attack, or myocardial infarction (MI), citing conflicting data about the safety and effectiveness of drug-eluting stents in this patient group. Such concerns are being challenged by an analysis of a large Massachusetts database.

March 31, 2008 - New evidence from a large randomized study is answering important questions about the best approach to percutaneous coronary intervention (PCI) in patients with a type of heart attack known as ST-segment-elevation myocardial infarction (STEMI). In the study, drug-eluting stents outperformed bare-metal stents, and high-dose tirofiban, an anti-clotting medication, proved to be equally effective and have fewer side effects than the catheter lab standard, abciximab.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now